Table 1.
Characteristics of patients at baseline.
| n = 156 | |
|---|---|
| Age, mean (SD), years | 63.7 (11.0) |
| Sex, no. (%) | |
| Male | 67.3% |
| Female | 32.7% |
| Type of AF, no. (%) | |
| Paroxysmal | 30.8% |
| Persistent | 65.4% |
| Long-standing | 4.8% |
| Duration of AF, mean (SD), years | 3.3 (5.0) |
| Hypertension, no. (%) | 73 (46.8) |
| Post MI, no (%) | 16 (10.3) |
| Dilated cardiomyopathy, no. (%) | 5 (3.2) |
| Hypertrophic cardiomyopathy, no. (%) | 1 (0.6) |
| Ischaemic cardiomyopathy, no. (%) | 11 (7.1) |
| Stroke, transient ischaemic attack, peripheral embolism, no. (%) | 16 (10.9) |
| Diabetes, no. (%) | 28 (17.9) |
| Coronary heart disease, no. (%) | 21 (13.5) |
| Valvular heart disease, no. (%) | 16 (10.3) |
| CHA2DS2-VASc score, mean (SD) | 2.37 (1.45) |
| MYHA class, no. (%) | |
| I | 28 (17.9) |
| II | 52 (33.3) |
| III | 62 (39.7) |
| IV | 14 (9.0) |
| LVEF, mean (SD), % | 37.9 (7.8) |
| NT-proBNP, mean (SD), pg/ml | 640 (934.8) |
| TnI, mean (SD), ng/ml | 0.06 (0.17) |
| D-dimer, mean (SD), mg/l | 0.61 (1.26) |
| Oral anticoagulation (%) | 152 (97.4) |
| β blocker used (%) | 66 (42.3) |
| ARNI used (%) | 71 (45.2) |
| ACEI/ARB used (%) | 67 (42.9) |
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; MI, myocardial infarction.